Therapeutic antibodies and its use in COVID-19: a review

P U Monica , Tera Sony

Monoclonal antibodies, Immunoglobulin G, Hybridoma technology, Covid-19, Cancer treatment

Proteins, Peptides, Monoclonal antibodies, gene therapy, cell therapy and RNAi (RNA Interference) come under large therapeutic molecules. These are progressively represented as new molecular entities registered through the FDA (Food and Drug Administration). The majority of NME’s (New Molecular Entities) registered to date, are still small molecules. Under antibody-therapeutics, since 2019, in clinical trials over 82 antibody- NMEs (New Molecular Entities) have been approved to treat diseases with hundreds more. The development of antibody-based bio-pharmaceutics for effective and safe treatment of many diseases like autoimmune, oncology, transplantation and inflammatory disorders has shown noteworthy success in the last three decades. Development and significant rapid growth leading to clinical success began in the 1990s. Over 80 regulatory approvals have demonstrated this fact. Since 2015, it is estimated that more than 100 therapeutic antibodies, such as monoclonal antibodies ( mAbs), have entered first-in-human (FIH) studies per year and 700 antibody-based therapeutics are currently in some stage of clinical development.

Published Paper   E-Certificate

"Therapeutic antibodies and its use in COVID-19: a review", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.8, Issue 7, page no.233 - 240, July-2023, Available :https://ijsdr.org/papers/IJSDR2307031.pdf

Volume 8 Issue 7, July-2023

Pages : 233 - 240

Paper Reg. ID: IJSDR_207589

Published Paper Id: IJSDR2307031

Downloads: 000347234

Research Area: Pharmacy

Country: hyderabad, telangana, india

Published Paper PDF: https://ijsdr.org/papers/IJSDR2307031

Published Paper URL: https://ijsdr.org/viewpaperforall?paper=IJSDR2307031

ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJSDR(IJ Publication) Janvi Wave

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition